Press Releases Inventiva

Equities

IVA

FR0013233012

Market Closed - Euronext Paris Other stock markets 11:35:06 2024-05-09 am EDT			5-day change	1st Jan Change
3.195 ^EUR	-1.99%		+7.94%	-21.98%

Apr. 22	Inventiva: UBS Group falls below 5% threshold	CF
Apr. 18	Transcript : Inventiva S.A. - Special Call

Press Releases

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Inventiva : Présentation corporate avril 2024	Apr. 30	PU
Inventiva announces filing of its 2023 Universal Registration Document and 2023 Annual Report on Form 20-F	Apr. 03	GL
Inventiva announces the nomination of Andre Turenne as Director	Mar. 28	GL
Inventiva reports its 2023 full-year results	Mar. 27	GL
Inventiva announces the schedule of publication and presentation of its 2023 Full-Year Financial Results	Mar. 22	GL
Inventiva announces positive results from the Phase II, LEGEND, Proof-of-Concept study combining lanifibranor with empagliflozin in patients with MASH/NASH and T2D	Mar. 18	GL
Inventiva announces positive results from the Phase II, LEGEND, Proof-of-Concept study combining lanifibranor with empagliflozin in patients with MASH/NASH and T2D	Mar. 18	AQ
Inventiva to present the results of LEGEND Phase IIa combination trial with lanifibranor and empagliflozin in patients with MASH/NASH and T2D	Mar. 13	GL
Inventiva to present the results of LEGEND Phase IIa combination trial with lanifibranor and empagliflozin in patients with MASH/NASH and T2D	Mar. 13	AQ
Inventiva announces that screening in the NATiV3, Phase III, clinical trial evaluating lanifibranor in NASH has resumed	Mar. 07	GL
Inventiva : Corporate Presentation March 2024	Mar. 01	PU
Inventiva reports preliminary 2023 fiscal year financial Information¹ and provides an update on its clinical trial NATiV3	Feb. 15	GL
Inventiva reports preliminary 2023 fiscal year financial Information¹ and provides an update on its clinical trial NATiV3	Feb. 15	AQ
Half-Year Review of Inventiva’s Liquidity Contract with Kepler Cheuvreux	Jan. 24	GL
Inventiva draws down the second tranche of €25 million under existing Finance Contract with the European Investment Bank	Jan. 10	GL
Inventiva draws down the second tranche of €25 million under existing Finance Contract with the European Investment Bank	Jan. 10	AQ
Inventiva announces the randomization of the first patient in China in the NATiV3 clinical trial and provides an update on its clinical development program	Dec. 20	GL
Inventiva announces the positive recommendation of the third DMC of the Phase III clinical trial with lanifibranor in patients with NASH	Dec. 04	GL
Inventiva announces the positive recommendation of the third DMC of the Phase III clinical trial with lanifibranor in patients with NASH	Dec. 04	AQ
Inventiva reports 2023 Third Quarter Financial Information¹	Nov. 21	GL

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Press Releases Inventiva

Equities

IVA

FR0013233012

Press Releases

Filters